Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drugs in the pipeline for public health diseases

17.11.2005


Swedish chemists synthesizing substances for blood clots, malaria, and hepatitis C.



Chemists at Linköping University in Sweden have developed three types of molecules, protease inhibitors, that can be further developed into drugs for cardiovascular diseases, malaria, and hepatitis C.

Proteases are a group of enzymes that play a major role in the course of certain diseases. If there is a molecule present that prevents the protease from working, the disease can be cured. Such substances are called inhibitors and are already in use in many drugs today.


Per-Ola Johansson, a doctoral candidate in organic chemistry, describes in his dissertation the synthesis of such protease inhibitors, designed for potential use in combating three different diseases: cardiovascular diseases (to prevent the formation of blood clots), malaria, and chronic jaundice of the type hepatitis C.

Thrombin is a protease that plays a key role when blood coagulates. In some individuals this process is hyperactive, which can lead to the formation of blood clots. The research team at Linköping University has synthesized a series of molecules that inhibit the activity of thrombin in varying degrees. The most active of these molecules give an indication of how to go about creating the optimal thrombin inhibitor to develop a functioning drug.

Malaria, which affects some 500 million people annually, killing nearly 2 million of them, is caused by a single-cell parasite that breaks down the hemoglobin in red blood corpuscles. For tools, the parasite makes use of a number of different protease enzymes. The research team has developed a large number of molecules that inhibit the activity of two of these, plasmepsin I and II. Some of these inhibitors have proven to be extremely effective and could be optimized to become a powerful new malaria drug.

Hepatitis C is caused by the virus HCV. When it proliferates, HCV forms a chain-shaped molecule that is cut in smaller pieces by various protease enzymes, and these pieces then build up new virus particles. The team has synthesized a series of inhibitors of NS3, one of the most important of these enzymes.

This work has been carried out under the supervision of Professor Ingemar Kvarnström, Professor Bertil Samuelsson, and Åsa Rosenquist, Ph.D., and in collaboration with the pharmaceutical companies Medivir and Astra Zeneca.

The dissertation is titled Design and synthesis of inhibitors that target the serine protease thrombin, the malarial aspartyl proteases plasmepsin I and II, and the hepatitis C virus NS3 serine protease.

Åke Hjelm | alfa
Further information:
http://www.liu.se

More articles from Life Sciences:

nachricht Microscope measures muscle weakness
16.11.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

nachricht Good preparation is half the digestion
16.11.2018 | Max-Planck-Institut für Stoffwechselforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>